Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Defective in cullin neddylation 1 domain-containing protein 3 (DCUN1D3) is a member of the DCNL (Defective in cullin neddylation-like) protein family that facilitates the transfer of the ubiquitin-like protein NEDD8 onto cullin proteins, thereby regulating the activity of cullin-RING E3 ubiquitin ligases such as the SCF (SKP1–CUL1–FBOX) complex[1][2][3][6]. DCUN1D3 plays a role in cell cycle progression, especially after UV-induced DNA damage, by modulating p27 protein degradation through the regulation of cullin neddylation and subsequent SCF^SKP2^ E3 ligase activity[1][2]. Knockdown of DCUN1D3 can block S phase progression and result in increased levels of the cell cycle inhibitor p27, implicating a function in cell growth and survival and suggesting possible tumor suppressor or cancer-related roles[1][2][5]. The protein localizes to both the cytoplasm and nucleus and its expression is induced by UV damage[1][2][3][5]. No direct therapeutic targeting, drugs, or use as a biomarker have been established in the current literature[2][5][6]. DCUN1D3 is involved in cullin neddylation and SCF ubiquitin ligase regulation, functions key to cell cycle control and DNA damage response[1][2][3][5][6]. It is not a classical therapeutic target (e.g., receptor, enzyme, transporter); rather, it is an E3 ligase-associated cofactor and neddylation regulator[1][2][3]. Disease roles are proposed mainly in cancer-related cell cycle regulation but evidence for direct clinical application or drug targeting is lacking[1][2][6]. No drugs are currently known to directly interact with DCUN1D3, and there are no established mechanisms of action relevant to drug targeting, biomarker roles, or safety concerns according to available references[2][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Defective in cullin neddylation 1 domain-containing protein 3 (DCUN1D3).